Photo from ESMOGI24/LinkedIn
Jun 28, 2024, 10:40
The final results of the KEYNOTE-585 study presented at ESMOGI24
ESMO shared on LinkedIn:
“The final results of the KEYNOTE-585 study presented at ESMOGI24 suggest that the current treatment standard for resectable gastric/gastro-oesophageal junction cancers should remain unchanged.
Event-free survival was not significantly improved with pembrolizumab plus chemotherapy compared to placebo plus chemotherapy or placebo plus FLOT.
According to Elizabeth Smyth however, the increase in the pathological complete response rate seen with the addition of pembrolizumab suggests it may improve response to chemotherapy in at least some patients.
To learn more about this topic, read the ESMO Daily Reporter article.”
Source: ESMO/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 3, 2024, 11:53
Dec 3, 2024, 11:50
Dec 3, 2024, 11:43
Dec 3, 2024, 09:35